Primary hyperaldosteronism historical perspective
|
Primary hyperaldosteronism Microchapters |
|
Differentiating Primary Hyperaldosteronism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary hyperaldosteronism historical perspective On the Web |
|
American Roentgen Ray Society Images of Primary hyperaldosteronism historical perspective |
|
Primary hyperaldosteronism historical perspective in the news |
|
Risk calculators and risk factors for Primary hyperaldosteronism historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
- Primary hyperaldosteronism (Conn's syndrome) was described for the first time by the Polish internist Michał Lityński.[1]
- In 1955, Dr Jerome W. Conn the American endocrinologist first described the condition and named it Conn's syndrome. [2][3]
- By 1964, Conn had collected 145 cases, and he postulated that up to 20% of patients with essential hypertension might have primary aldosteronism and later stated that the actual prevalence may be less than he previously thought. He predicted prevalence of primary aldosteronism to be 10% of hypertensives, a prediction that became true nearly 40 years later.[4]
- From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling.
- On October 19, 1964, Jerome W. Conn, Edwin L. Cohen and David R. Rovner differentiated between primary and secondary aldosteronism in hypertensive disease.[5]
- In 1970s, there was an extensive application of modern imaging modalities, such as CT scanning, adrenal venous sampling and steroid analysis.[6]
- From 1980s, more and more patients with primary aldosteronism were screened out from the hypertensive population by plasma renin activity/plasma aldosterone concentration ratio and cured by surgical interventions; laparoscopic unilateral adrenalectomy has become the generally accepted golden standard of operation.[7]
References
- ↑ Kucharz EJ (2007). "[Michał Lityński--a forgotten author of the first description on primary hyperaldosteronism]". Pol. Arch. Med. Wewn. (in Polish). 117 (1–2): 57–8. PMID 17642209.
- ↑ Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians 1955;68:215-31; discussion, 231-3. PMID 13299331.
- ↑ "Grand Rounds: Primary Aldosteronism, Beyond Conn's Syndrome | Clinical Correlations".
- ↑ CONN JW, KNOPF RF, NESBIT RM (1964). "CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES". Am. J. Surg. 107: 159–72. PMID 14099489.
- ↑ Conn JW, Cohen EL, Rovner DR (1985). "Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner". JAMA. 253 (4): 558–66. PMID 3881606.
- ↑ Lingam RK, Sohaib SA, Vlahos I, Rockall AG, Isidori AM, Monson JP, Grossman A, Reznek RH (2003). "CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland". AJR Am J Roentgenol. 181 (3): 843–9. doi:10.2214/ajr.181.3.1810843. PMID 12933492.
- ↑ Rayner BL, Opie LH, Davidson JS (2000). "The aldosterone/renin ratio as a screening test for primary aldosteronism". S. Afr. Med. J. 90 (4): 394–400. PMID 10957926.